NRX Pharmaceuticals, Inc. Common Stock (NRXP) Stock
Key stats
- Market cap
- $105.64M
- Price / Earnings ratio
- -4.4x
- EPS (TTM)
- -$0.55
- Volume
- Loading
- 52-week high
- $5.06
- 52-week low
- $1.62
Source: third-party data provider, as of November 13, 2026
Compare with NRXP
Recent news

NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
NRXP

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
NRXP

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
NRXP

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
NRXP
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 44.57
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.16
- MACD histogram
- 0.02
- SMA 50
- $2.87
- Price below SMA 50
- EMA 50
- $2.79
- Price below EMA 50
- SMA 200
- $2.97
- Price below SMA 200
- EMA 200
- $2.83
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
NRXP

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
NRXP

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
NRXP

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
NRXP

NRx Pharmaceuticals Q1 Earnings Call Highlights
NRx Pharmaceuticals Q1 Earnings Call Highlights
NRXP

NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
NRXP

New Strong Sell Stocks for January 27th
New Strong Sell Stocks for January 27th
NRXP

Why Did NRXP Stock Surge 21% Pre-Market Today?
Why Did NRXP Stock Surge 21% Pre-Market Today?
NRXP

New Strong Buy Stocks for December 30th
New Strong Buy Stocks for December 30th
NRXP

New Strong Buy Stocks for December 26th
New Strong Buy Stocks for December 26th
NRXP
News tone: automated (AI) classification of the article's content, not a price prediction.
About NRX Pharmaceuticals, Inc. Common Stock
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chairman & CEO | 1957 |
| Mr. Michael S. Abrams M.B.A. | CFO & Treasurer | 1970 |
| Mr. Joseph M. Casper | Chief Operating Officer | 1951 |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer | 1962 |
| Dr. Hervé Perron HDR, Ph.D. | Chief Scientist | 1959 |
| Suzanne Messere | Investor Relations | — |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist | 1947 |
| Dr. Dennis K. McBride Ph.D. | Chief Strategy Officer & Director | 1955 |
| Prof. Joshua C. Brown M.D., Ph.D. | Chief Medical Innovation Officer | — |
| Mr. Glenn D. Tyson | Chief Commercial Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 44.57
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.16
- MACD histogram
- 0.02
- SMA 50
- $2.87
- Price below SMA 50
- EMA 50
- $2.79
- Price below EMA 50
- SMA 200
- $2.97
- Price below SMA 200
- EMA 200
- $2.83
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $35.33
- High
- $51.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +18.3 | +43.0 | -11.5 | -18.4 | +7.4 | -15.1 | -20.4 | +12.4 |



